Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Fri, 28.01.2022
HAEMATO AG
PCR PoC-Device added to the product portfolio; revenue and earnings
forecasts unchanged, upside potential anticipated from new products, price
target and BUY rating confirmed
In our last management interview (http://www.more-ir.de/d/23165.pdf) on the
current developments of HAEMATO AG, the CEO Patrick Brenske had announced
the addition of a mobi [ … ]
Mon, 24.01.2022
Defence Therapeutics Inc.
GBC Research Watchlist: Defence Therapeutics
Defence Therapeutics is led by Sebastien Plouffe. Mr. Plouffe has been a
successful Investment Advisor and CEO notably in the resource sector,
leading several junior companies to profitable exits. Mr. Plouffe is
supported by Dr. Moutih Rafei, VP R&D and Dr. Simon Beaudoin CTSO. Dr.
Rafei is a worl [ … ]
Wed, 19.01.2022
The NAGA Group AG
Strong revenue and earnings growth in 2021; guidance for 2022 significantly
above our expectations; estimates and share price target raised
According to preliminary figures for the past financial year 2021, The NAGA
Group AG (short to: NAGA) achieved significant revenue growth as expected.
Compared to the previous year, consolidated sales more t [ … ]
Mon, 27.12.2021
Cryptology Asset Group PLC
Cryptology is a leading European holding company for crypto assets and
blockchain companies.
Cryptology Asset Group is a publicly traded investment company focused on
crypto-assets and blockchain-based business models. For this purpose,
Cryptology has a broad network of experts, including Christian Angermayer
and Mike Novogratz, two of the most [ … ]
Tue, 21.12.2021
Saturn Oil & Gas Inc.
Record quarter production 6,970 boe/d
Record quarter Free Cash Flow $9.5M CAD
Record production. The company has produced 6,970 boe/d during Q3-2021.
This represents an increase of 270% over their Q2 results and 1297% over Q3
2020.
Record Free Cash Flow. The company Q3 EBITDA resulted in $17.2M CAD. The
company posted a $9.5M CAD positive fr [ … ]
Tue, 21.12.2021
Cogia AG
Dynamic growth with patented semantic solutions in the area of 'Big Data
Analytics'
Cogia AG is a full-service provider of AI-based, patented, semantic
solutions and services in the field of 'Big Data Analytics', with a focus
on customer experience, monitoring and engagement. Cogia's goal is to
support its customers, whether companies, associati [ … ]
Mon, 13.12.2021
Aspermont Limited
Preliminary FY2021 shows positive Net Profit After Tax
FY2021 preliminary report shows continued growth
As per their preliminary numbers, the company has delivered on all their
guidance:
- Overall growth
- Subscriptions growth rate to go back to pre-Covid-19 levels
- Growth in audience
- High growth in new products
- Continue [ … ]
Fri, 10.12.2021
HAEMATO AG
In operational terms, HAEMATO AG is heading for a record year following the
acquisition of M1 Aesthetics GmbH. In addition, the expansion of their
private label business is increasingly coming into focus. In this regard,
the company plans to expand its portfolio with a botulinum toxin product
under its own brand. GBC analyst Cosmin Filker spoke wi [ … ]
Thu, 09.12.2021
EasyMotionSkin Tec AG
Successful listing of EasyMotionSkin Tec AG on the m:access of the Munich
Stock Exchange
On 09.12.2021 EasyMotionSkin Tec AG was successfully listed on the m:access
of the Munich Stock Exchange. The initial share price is 14.50 EUR.
According to the management, no extensive capital market transactions are
planned in the near future.
The EasyMo [ … ]
Mon, 06.12.2021
Defence Therapeutics Inc.
'We can work on any disease and adapt to any emergent pandemic such as the
one related to SARS-CoV2'
In its current letter to shareholders, Defence Therapeutics reports the
successful completion of its protein-based COVID vaccine (AccuVAC-PT001)
toxicology studies in non-rodent rabbit model. The AccuVAC-PT001 vaccine is
an injectable vaccine cap [ … ]
